The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field

Abstract

What it is known about leukotriene receptor antagonists? •Leukotriene receptor antagonist, such as montelukast and zafirlukast, is used in asthma, COPD, and allergic rhinitis. • Montelukast is the most prescribed CysLT antagonist used in asthmatic patients. • Different in vivo animal studies have shown that leukotriene receptor antagonists can prevent the atherosclerosis progression, and have a protective role after cerebral ischemia. What we still need to know? • Today, there is a need for conducting clinical trials to assess the role of montelukast in reducing cardiovascular risk and to further understand the mechanism of action behind this effect.

Montelukast, an Anti-asthmatic Drug, Inhibits Zika Virus Infection by Disrupting Viral Integrity

“…Montelukast, one of the leukotriene receptor antagonists, is the most prescribed cysteinyl leukotriene 1 (CysLT1) antagonist safely used in asthmatic patients for many years (Hoxha et al, 2017). It is interesting that montelukast exhibited potential antiviral efficacy against ZIKV in vitro and in vivo.…”

Leukotriene receptors as potential therapeutic targets

“…This drug is effective in allergic rhinitis and several types of asthma, e.g., exerciseinduced asthma, asthma in obese patients, asthma in smokers, and aspirin-induced asthma (176,177). The beneficial effect of montelukast in cardiovascular disease has been under clinical trial (178)(179)(180). Pranlukast is an orally administered, selective, and competitive antagonist.…”

Leukotrienes and sex: strange bedfellows?

“…For example, Pace et al focus primarily on inflammatory processes and leukocytes that predominantly generate LTB 4 . Although a number of inflammatory diseases, including scleroderma lung disease (13), inflammatory bowel disease (6), sickle cell disease (14), and cardiovascular disease (15), are reported to be associated with increased LTB 4 levels, there are few, if any, examples in which treatment of these diseases with leukotriene synthesis inhibitors has shown benefit. The diseases in which there is the most information relevant to leukotriene biology are asthma, AERD, and allergic rhinitis, to which cysteinyl leukotrienes are known to contribute.…”